Talawar bets bispecific approach can shake up eczema market
Source: news.google.com
Published: Jun 29, 2026 13:54
Source: news.google.com
Published: Jun 29, 2026 13:54
Related Stories
Alfasigma bets on rheumatology growth as filgotinib advances in axSpA The Pharma Letter
#Biotech HeadlinesWhen Back Pain Won’t Quit: A Large Clinical Trial Points to the Power of Self-Management UPMC
#Clinical TrialsBiotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in children's bone disease Endpoints News
#Biotech HeadlinesDupilumab Improves Outcomes for EoG in Phase 2 Clinical Trial PR Newswire
#Clinical TrialsDupilumab Improves Outcomes for EoG in Phase 2 Clinical Trial Morningstar
#Clinical TrialsTalawar Tx launches as publicly traded biotech The Pharma Letter
#Biotech HeadlinesAdd Shortcut
Open this site faster like an app from your phone home screen.